

08 February 2022

Subject: Rheumatology Biologics

Question 1:

We are analysing the usage of biologic and biosimilar products within Rheumatology. It would be really helpful if you could provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 3 months with the following drugs:

Response below:

Biologic - Current	Total
Abatacept	58
Adalimumab (Humira)	411
Amgevita	32
Anakinra	13
Apremilast	31
Baracitinib	58
Belimumab	<5
Benepali (Etanercept)	361
Benlysta (Belimumab)	<5
Canakinumab	<5
Certolizumab (Cimzia)	111
Etanercept (Enbrel)	134
Golimumab	115
Guselkumab	<5
Imraldi (Adalimumab)	673
Infliximab (Remicade)	53
Remsima (Infliximab)	50
Rituximab	100
S/c Remsima (Infliximab)	<5
Sarilumab	5
Seckukinumab	213
subcut Abatacept	128
Sub-cut Tocilizumab	123
Taltz (Ixekizumab)	62
Tocilizumab	47
Tofacitanib	38
Truxima	294
Upadacitinib	42
Ustekinumab	18